Adenosine Inhibits Cholangiocarcinoma by a Concurrent Activation of AMPK and mTORC1 Signaling Pathways
Anticancer Research · 2026
DOI: 10.21873/anticanres.18040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Jomnarong Lertsuwan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology, Chulabhorn Research Institute, Bangkok, Thailand; jomnarong@cri.or.th. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Mechanistic Target of Rapamycin Complex 1, Signal Transduction, Bile Duct Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunology, Chulabhorn Research Institute, Bangkok, Thailand; jomnarong@cri.or.th.
- Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand.
- Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand jutamaad@cri.or.th.
Zitieren
APA
Lertsuwan, J., Svasti, J., & Satayavivad, J. (2026). Adenosine Inhibits Cholangiocarcinoma by a Concurrent Activation of AMPK and mTORC1 Signaling Pathways. Anticancer Research. https://doi.org/10.21873/anticanres.18040
Vancouver
Lertsuwan J, Svasti J, Satayavivad J. Adenosine Inhibits Cholangiocarcinoma by a Concurrent Activation of AMPK and mTORC1 Signaling Pathways. Anticancer Research. 2026. doi:10.21873/anticanres.18040
BibTeX
@article{Lertsuwan2026,
author = {Lertsuwan, Jomnarong and Svasti, Jisnuson and Satayavivad, Jutamaad},
title = {Adenosine Inhibits Cholangiocarcinoma by a Concurrent Activation of AMPK and mTORC1 Signaling Pathways},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18040}
}
EUVIMED